iRhythm Acquired VitalConnect for $237.5 Million

The all-cash acquisition expands iRhythm's cardiac monitoring capabilities into hospital and remote care settings.

Updated on Oct. 5, 2026 in Healthcare

Isometric editorial illustration of two clean, minimalist cardiac monitoring patch sensors resting on a neutral platform, evoking medical technology integration. — iRhythm has finalized its $237.5 million acquisition of VitalConnect, a move designed to integrate multi-vitals monitoring capabilities into their existing cardiac services. AI Illustration. Upload story photo >

Live Poll

Do you trust that consolidation of medical monitoring companies results in better care for patients?

iRhythm has completed its $237.5 million all-cash acquisition of VitalConnect. The deal aims to strengthen the company's multi-vitals strategy and broaden its reach across hospital and remote monitoring environments.

Why it matters

By integrating VitalConnect's technology, iRhythm intends to enhance its cardiac monitoring services and support its long-term financial targets. The merger is expected to accelerate revenue growth while addressing the needs of those at risk for arrhythmias.

The deal includes a $237.5 million cash payment and $10 million in provided working capital. VitalConnect brings specialized tech capable of monitoring 11 distinct physiological parameters.

The players

iRhythm

This company is a leading provider of digital healthcare solutions focused on cardiac monitoring and diagnostic services.

VitalConnect

This firm specializes in developing wearable biosensor technology for the remote monitoring of multiple physiological parameters.

The details

The companies are currently aligning teams and engaging existing customers to merge their operational footprints. iRhythm is leveraging its established national presence to scale the availability of VitalConnect services in various clinical settings.

iRhythm completed the acquisition of VitalConnect on October 5, 2026.

Market Landscape

This acquisition reflects the broader trend toward consolidating specialized diagnostic technologies to better serve remote patient populations. It positions iRhythm to compete more effectively by integrating comprehensive vital sign tracking into its existing cardiac diagnostic portfolio.

Patients and healthcare providers may gain access to more integrated monitoring services as the companies merge their product suites. Hospitals can expect more streamlined workflows for remote cardiac care as the firms align their service delivery models.

The takeaway

This deal underscores the industry move toward multi-parameter health monitoring to improve diagnostic accuracy for millions of at-risk individuals. Executives plan to maintain a 15% adjusted EBITDA margin target by 2027 as they scale these combined operations.